These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20652060)

  • 1. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat).
    Ferreira L; Teixeira-de-Lemos E; Pinto F; Parada B; Mega C; Vala H; Pinto R; Garrido P; Sereno J; Fernandes R; Santos P; Velada I; Melo A; Nunes S; Teixeira F; Reis F
    Mediators Inflamm; 2010; 2010():592760. PubMed ID: 20652060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat).
    Mega C; de Lemos ET; Vala H; Fernandes R; Oliveira J; Mascarenhas-Melo F; Teixeira F; Reis F
    Exp Diabetes Res; 2011; 2011():162092. PubMed ID: 22203828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model.
    Gonçalves A; Leal E; Paiva A; Teixeira Lemos E; Teixeira F; Ribeiro CF; Reis F; Ambrósio AF; Fernandes R
    Diabetes Obes Metab; 2012 May; 14(5):454-63. PubMed ID: 22151893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitagliptin reduces hyperglycemia and increases satiety hormone secretion more effectively when used with a novel polysaccharide in obese Zucker rats.
    Reimer RA; Grover GJ; Koetzner L; Gahler RJ; Juneja P; Lyon MR; Wood S
    J Nutr; 2012 Oct; 142(10):1812-20. PubMed ID: 22915295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin Protects Cardiac Function by Reducing Nitroxidative Stress and Promoting Autophagy in Zucker Diabetic Fatty (ZDF) Rats.
    Zhou Y; Wang H; Man F; Guo Z; Xu J; Yan W; Li J; Pan Q; Wang W
    Cardiovasc Drugs Ther; 2018 Dec; 32(6):541-552. PubMed ID: 30328028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties.
    Mega C; Vala H; Rodrigues-Santos P; Oliveira J; Teixeira F; Fernandes R; Reis F; de Lemos ET
    Diabetol Metab Syndr; 2014 Mar; 6(1):42. PubMed ID: 24650557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats.
    Apaijai N; Pintana H; Chattipakorn SC; Chattipakorn N
    Br J Pharmacol; 2013 Jul; 169(5):1048-57. PubMed ID: 23488656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of concomitant administration of L-glutamine and cycloart-23-ene-3β, 25-diol (B2) with sitagliptin in GLP-1 (7-36) amide secretion, biochemical and oxidative stress in streptozotocin - nicotinamide induced diabetic Sprague Dawley rats.
    Badole SL; Chaudhari SM; Bagul PP; Mahamuni SP; Khose RD; Joshi AC; Raut CG; Zanwar AA
    PLoS One; 2013; 8(8):e72817. PubMed ID: 24023648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
    Takai S; Sakonjo H; Jin D
    J Pharmacol Sci; 2014; 125(4):386-93. PubMed ID: 25030743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals.
    Marques C; Mega C; Gonçalves A; Rodrigues-Santos P; Teixeira-Lemos E; Teixeira F; Fontes-Ribeiro C; Reis F; Fernandes R
    Mediators Inflamm; 2014; 2014():538737. PubMed ID: 24817793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome.
    Tofovic DS; Bilan VP; Jackson EK
    Clin Exp Pharmacol Physiol; 2010 Jul; 37(7):689-91. PubMed ID: 20374254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitagliptin exerts an antinflammatory action.
    Makdissi A; Ghanim H; Vora M; Green K; Abuaysheh S; Chaudhuri A; Dhindsa S; Dandona P
    J Clin Endocrinol Metab; 2012 Sep; 97(9):3333-41. PubMed ID: 22745245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum level of soluble CD26/dipeptidyl peptidase-4 (DPP-4) predicts the response to sitagliptin, a DPP-4 inhibitor, in patients with type 2 diabetes controlled inadequately by metformin and/or sulfonylurea.
    Aso Y; Ozeki N; Terasawa T; Naruse R; Hara K; Suetsugu M; Takebayashi K; Shibazaki M; Haruki K; Morita K; Inukai T
    Transl Res; 2012 Jan; 159(1):25-31. PubMed ID: 22153807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes.
    Mu J; Petrov A; Eiermann GJ; Woods J; Zhou YP; Li Z; Zycband E; Feng Y; Zhu L; Roy RS; Howard AD; Li C; Thornberry NA; Zhang BB
    Eur J Pharmacol; 2009 Nov; 623(1-3):148-54. PubMed ID: 19765579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients.
    Koren S; Shemesh-Bar L; Tirosh A; Peleg RK; Berman S; Hamad RA; Vinker S; Golik A; Efrati S
    Diabetes Technol Ther; 2012 Jul; 14(7):561-7. PubMed ID: 22512265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
    Jackson EK; Mi Z; Tofovic SP; Gillespie DG
    Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sitagliptin as add-on therapy in insulin deficiency: biomarkers of therapeutic efficacy respond differently in type 1 and type 2 diabetes.
    Giampietro O; Giampietro C; Bartola LD; Masoni MC; Matteucci E
    Drug Des Devel Ther; 2013; 7():99-104. PubMed ID: 23439744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the exocrine pancreas in the male Zucker diabetic fatty rat model of type 2 diabetes mellitus following 3 months of treatment with sitagliptin.
    Forest T; Holder D; Smith A; Cunningham C; Yao X; Dey M; Frederick C; Prahalada S
    Endocrinology; 2014 Mar; 155(3):783-92. PubMed ID: 24424056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.
    Dobrian AD; Ma Q; Lindsay JW; Leone KA; Ma K; Coben J; Galkina EV; Nadler JL
    Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E410-21. PubMed ID: 21081706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition.
    Rizzo MR; Barbieri M; Marfella R; Paolisso G
    Diabetes Care; 2012 Oct; 35(10):2076-82. PubMed ID: 22688551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.